QT dispersion and late potentials during doxorubicin therapy for non- Hodgkin's lymphoma

Journal of Internal Medicine

Volumn 245, Issue 4, 1999, Pages 359-364

  Nousiainen, Tapio ^a   Vanninen, E ^a   Rantala, A ^a   Jantunen, E ^a   Hartikainen, J ^a  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Depolarization; Doxorubicin; Late potentials; QT dispersion; Repolarization

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; VINCRISTINE;

ADULT; AFTERDISCHARGE; AGED; ARTICLE; CLINICAL ARTICLE; ELECTROCARDIOGRAPHY; FEMALE; HEART DEPOLARIZATION; HEART LEFT VENTRICLE FAILURE; HEART RATE; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHODGKIN LYMPHOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QT INTERVAL; RISK ASSESSMENT; SUDDEN DEATH;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; DOXORUBICIN; ELECTROCARDIOGRAPHY; FEMALE; HEART CONDUCTION SYSTEM; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SIGNAL PROCESSING, COMPUTER-ASSISTED;

EID: 0032905116     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1999.00480.x     Document Type: Article

References (30)

1. 1 Praga C, Beretta G, Vigo PL, Lenaz GR, Pollini C, Bonadonna G et al. Adriamycin cardiotoxicity: a survey of 1273 patients. Cancer Treat Rep 1979; 63: 827-34.
2. 2 Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. A clinicopathologic analysis of Adriamycin cardiotoxicity. Cancer 1973; 32: 302-14.
3. 3 Postma A, Bink-Boelkens MTE, Beaufort-Krol GCM, Kengen RAM, Elzenga NJ, Schasfoort-van Leeuwen MJM et al. Late cardiotoxicity after treatment for a malignant bone tumor. Med Pediatr Oncol 1996; 26: 230-37.
4. 4 Day CP, Mccomb JM, Campbell RWF. QT dispersion: an indication of arrhythmia risk in patients with long QT intervals. Br Heart J 1990; 63: 342-44.
5. 5 Cowan JC, Yusoff K, Moore M, Amos PA, Gold AE, Bourke JP et al. Importance of lead selection in QT interval measurement. Am J Cardiol 1988; 61: 83-87.
6. 6 Day CP, Mccomb JM, Matthews J, Campbell RWF. Reduction in QT dispersion by sotalol following myocardial infarction. Eur Heart J 1991; 12: 423-27.
7. 7 Buja G, Miorelli M, Turrini P, Melacini P, Nava A. Comparison of QT dispersion in hypertrophic cardiomyopathy between patients with and without ventricular arrhythmias and sudden death. Am J Cardiol 1993; 72: 973-76.
8. 8 Perkiömäki JS, Koistinen MJ, Yli-Mäyry S, Huikuri HV. Dispersion of QT interval in patients with and without susceptibility to ventricular tachyarrhythmias after previous myocardial infarction. J Am Coll Cardiol 1995; 26: 174-79.
9. 9 Simson MB. Use of signals in the terminal QRS complex to identify patients with ventricular tachycardia after myocardial infarction. Circulation 1981; 64: 235-42.
10. 10 Denereaz D, Zimmermann M, Adamec R. Significance of ventricular late potentials in non-ischaemic dilated cardiomyopathy. Eur Heart J 1992; 13: 895-901.
11. 11 Mancini DM, Wong KL, Simson MB. Prognostic value of an abnormal signal-averaged electrocardiogram in patients with nonischemic congestive cardiomyopathy. Circulation 1993; 87: 1083-92.
12. 12 Gomes JA, Winters SL, Stewart D, Horowitz S, Milner M, Barreca P. A new noninvasive index to predict sustained ventricular tachycardia and sudden death in the first year after myocardial infarction: based on signal-averaged electrocardiogram, radionuclide ejection fraction and Holter monitoring. J Am Coll Cardiol 1987; 10: 349-57.
13. 13 AHA Medical/Scientific Statement. Standards for analysis of ventricular late potentials using high-resolution or signal-averaged electrocardiography. A statement by a Task Force Committee of the European Society of Cardiology, the American Heart Association, and the American College of Cardiology. Circulation 1991; 83: 1481-88.
14. 14 Kautzner J, Yi G, Camm AJ, Malik M. Short- and long-term reproducibility of QT, QTc, and QT dispersion measurement in healthy subjects. PACE 1994; 17: 928-37.
15. 15 Linker NJ, Colonna P, Kekwick CA, Till J, Camm J, Ward DE. Assessment of QT dispersion in symptomatic patients with congenital long QT syndromes. Am J Cardiol 1992; 69: 634-38.
16. 16 Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-10.
17. 17 Wackers FJ, Berger HJ, Johnstone DE, Goldman L, Reduto LA, Langou RA et al. Multiple gated cardiac blood pool imaging for left ventricular ejection fraction: validation of the technique and assessment of variability. Am J Cardiol 1979; 43: 1159-66.
18. 18 Mustonen P, Hippeläinen M, Vanninen E, Rehnberg S, Tenhumen-Eskelinen M, Hartikainen J. Significance of coronary artery bypass grafting-associated conduction defects. Am J Cardiol 1998; 81: 558-63.
19. 19 de Bruyne MC, Hoes AW, Kors JA, Hofman A, van Bemmel JH, Grobbee DE. QTc dispersion predicts cardiac mortality in the elderly. The Rotterdam Study. Circulation 1998; 97: 467-72.
20. 20 Naas AAO, Davidson NC, Thompson C, Cummings F, Ogston SA, Jung RT et al. QT and QTc dispersion are accurate predictors of cardiac death in newly diagnosed non-insulin dependent diabetes: cohort study. Br Med J 1998; 316: 745-46.
21. 21 Perkiömäki JS, Huikuri HV, Koistinen JM, Mäkikallio T, Castellanos A, Myerburg RJ. Heart rate variability and dispersion or QT interval in patients with vulnerability to ventricular tachycardia and ventricular fibrillation after previous myocardial infarction. J Am Coll Cardiol 1997; 30: 1331-38.
22. 22 von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia FM. Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases. Am J Med 1977; 62: 200-208.
23. 23 Bender KS, Shematek JP, Leventhal BG, Kan JS. QT interval prolongation associated with anthracycline cardiotoxicity. J Pediatr 1984; 105: 442-44.
24. 24 Ferrari S, Figus E, Cagnano R, Iantorno D, Bacci G. The role of corrected QT interval in the cardiologic follow-up of young patients treated with Adriamycin. J Chemother 1996; 8: 232-36.
25. 25 Schwartz CL, Hobbie WL, Truesdell S, Constine LC, Clark EB. Corrected QT interval prolongation in anthracycline-treated survivors of childhood cancer. J Clin Oncol 1993; 11: 1906-10.
26. 26 Tamminga RYJ, Bink-Boelkens MTE, Kievit J. Ventricular late potentials: another expression of cardiotoxicity of cytostatic drugs in children? Int J Cardiol 1992; 36: 283-88.
27. 27 Cripps TR, Counihan PJ, Frenneaux MP, Ward DE, Camm AJ, Mckenna WJ. Signal-averaged electrocardiography in hypertrophic cardiomyopathy. J Am Coll Cardiol 1990; 15: 956-61.
28. 28 Vester EG, Emschermann C, Stobbe U, Ochiulet-Vester J, Perings C, Kühl U, Schultheiss HP et al. Late potentials and heart rate variability in heart muscle disease. Eur Heart J 1994; 15(Suppl. C): 25-33.
29. 29 Steinherz LJ, Steinherz PG, Tan CTC, Heller G, Murphy L. Cardiac toxicity 4-20 years after completing anthracycline therapy. J Am Med Assoc 1991; 266: 1672-77.
30. 30 Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol 1995; 24: 352-61.